Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients

Leukemia

Volumn 12, Issue 10, 1998, Pages 1627-1629

  Mebis, J ^a   Goossens, H ^a   Bruyneel, P ^a   Sion, J P ^a   Meeus, I ^a   Van Droogenbroeck, J ^a   Schroyens, W ^a   Berneman, Z N ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Amikacin; Antibiotic resistance; Cefepime; Ceftazidime; Inducible Enterobacteriaceae; Neutropenic fever

Indexed keywords

AMIKACIN; AMPHOTERICIN B; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COTRIMOXAZOLE; GLYCOPEPTIDE; MEROPENEM; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; DRUG SENSITIVITY; ENTEROBACTERIACEAE; HUMAN; KLEBSIELLA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL;

EID: 0031660447     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401158     Document Type: Article

References (12)

1. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. New Engl J Med 1993; 18: 1323-1332.
2. Jacobson KL, Cohen SH, Inciardi JF, King JH, Lippert WE, Iglesias T, Vancouwenberghe CJ. The relationship between antecedent antibiotic use and resistance to extended spectrum cephalosporins in group I β-lactamase producing organisms. Clin Infect Dis 1995; 21: 1107-1113.
3. Sanders CC, Sanders WE. β-lactam resistance in Gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992; 15: 824-839.
4. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-590.
5. King JW, White MC, Todd JR, Conrad SA. Alterations in the microbial flora and in the incidence of bacteremia at a University Hospital after adoption of amikacin as the sole formulary aminoglycoside. Clin Infect Dis 1992; 14: 908-915.
6. Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America Joint Committee on the prevention of Antimicrobial Resistance. Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25: 584-599.
7. Cunha BA, Gill MV. Cefepime. Med Clin N Am 1995; 79: 721-732.
8. Pattyn SR, Sion JP, Verhoeven J. Evaluation of the LOGIC system for the rapid identification of members of the family Enterobacteriaceae in the clinical microbiology laboratory. J Clin Microbiol 1990; 28: 1449-1450.
9. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests: approved standard. NCCLS Document M2A4 (edn 4). National Committee for Clinical and Laboratory Standards: Villanova, Pennsylvania, 1990.
10. Burwen DR, Banderjee SN, Gaynes RP and the National Nosocomial Infections Surveillance System. Ceftazidime resistance among selected nosocomial Gram-negative bacilli in the United States. J Infect Dis 1994; 170: 1622-1625.
11. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance. Diagn Microbiol Infect Dis 1992; 15: 37S-42S.
12. Grassi GG, Grassi C. Cefepime: overview of activity in vitro and in vivo. J Antimicrob Chemother 1993; 32: (Suppl. B): 87-94.